Introduction
============

In 2008, lung cancer was the most commonly diagnosed cancer, accounting for 1.6 million new cancer cases and 13% of all new cancer cases. Lung cancer was also the leading cause of cancer-related mortality in males worldwide, responsible for 1.4 million mortalities, which corresponded to 18% of all cancer-related mortalities in 2008 ([@b1-ol-06-01-0220]). Surgical resection remains the treatment of choice for stage I and II non-small cell lung cancer (NSCLC) and also for certain patients with stage IIIA disease. A number of studies have shown that platinum-based adjuvant chemotherapy improves survival in completely resected NSCLC (R-NSCLC) ([@b2-ol-06-01-0220]--[@b4-ol-06-01-0220]).

Although adjuvant chemotherapy provides a clinically significant benefit, only between 5 and 15% of NSCLC patients receiving adjuvant chemotherapy ultimately benefit from an improved long-term survival ([@b5-ol-06-01-0220]). Given the toxic effects of chemotherapy and the resources required to administer this treatment, it would be useful to identify which NSCLC patients are likely to benefit from adjuvant chemotherapy prior to treatment. The optimization of current therapeutic strategies would greatly benefit from the identification of novel predictive factors, taking into account the patient's genetics and the biological characteristics of their disease. Such predictive factors may be used to effectively guide the clinician's decisions.

Antitubulin agents, including taxanes and vinorelbine, bind to microtubules and are widely used for the treatment of NSCLC. Microtubules are dynamic filamentous structures that are essential in eukaryotic cell proliferation, intracellular trafficking, signaling and migration. Microtubules are complex polymers consisting of tubulin dimers, each containing one α-tubulin and one β-tubulin molecule, and a variety of microtubule-associated proteins ([@b6-ol-06-01-0220]). In humans, β-tubulin exists as a variety of isotypes that mainly differ in their COOH-terminal sequences ([@b7-ol-06-01-0220]).

Little data is available on the expression of microtubule components in R-NSCLC tumor samples. Although the functional specificity of the various tubulin isotypes remains controversial, the expression patterns of certain tubulin isotypes are tissue-specific and the expression levels are correlated with the sensitivity to antitubulin agents ([@b8-ol-06-01-0220]--[@b12-ol-06-01-0220]). As access to frozen lung biopsy tissues for RNA analysis is often difficult, demonstrating that immunohistochemistry is able to provide useful predictive factors in NSCLC patients is likely to be beneficial for guiding the choice of chemotherapy regimens.

To assess whether the tubulin isotype level, as examined by immunohistochemistry, was able to identify predictive factors in R-NSCLC patients undergoing vinorelbine-based adjuvant chemotherapy, a retrospective study was performed on tumor samples from patients with R-NSCLC who were subsequently treated with vinorelbine-based regimens at The First Affiliated Hospital of Guangzhou Medical College (Guangzhou, China) between 2003 and 2008. The correlation between the biological results and the patient outcome was then investigated.

Patients and methods
====================

Patient data
------------

Tumor samples from 85 R-NSCLC patients treated between September 2003 and March 2008 at the First Affiliated Hospital of Guangzhou Medical College were analyzed. The histopathological subtypes were determined using the WHO classification for lung cancer. The current International Staging System for lung cancer was used for clinical disease staging ([@b13-ol-06-01-0220]). The clinicopathological characteristics of the patient population are shown in [Table I](#t1-ol-06-01-0220){ref-type="table"}. The median age at diagnosis was 57 years (range, 28--76 years). Subsequent to surgery, all patients were treated with vinorelbine in combination with cisplatin (CDDP) or carboplatin. The median follow-up time for the 85 patients was 31 months (range, 1--122 months), measured from the onset of chemotherapy.

The study was approved by the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China. Written informed consent was obtained from the patients or patient's family.

Immunohistochemistry
--------------------

The NSCLC tumor tissues were obtained by surgical excision. When possible, the diagnostic tumor blocks were used to ensure the availability of a sufficient number of viable, morphologically intact tumor cells to fulfill the scoring requirements and enable histopathological representation of the entire tumor. The tissue specimens were fixed in neutral buffered formalin, then embedded in paraffin wax and prepared as serial 3-*μ*m sections and attached to glass slides. The slides were placed in 10 mM citrate buffer (pH 6.0) for antigen retrieval, then the sections were incubated with normal rabbit serum, followed by anti-class II, III or IV β-tubulin antibodies (Sigma-Aldrich, St. Louis, MO, USA) at a dilution of 1:50. For the negative controls, the antibodies were substituted with phosphate-buffered saline (PBS).

Immunohistochemical staining was semi-quantitatively scored as −, +, ++ or +++ (score 3) on the basis of the percentage of positive cells (score 1) and the staining intensity (score 2), as shown in [Table II](#t2-ol-06-01-0220){ref-type="table"}. All slides were examined and scored independently by two pathologists blinded to the patient data.

Chemotherapy
------------

All patients received platinum-based regimens of 25 mg/m^2^ vinorelbine on days 1 and 8 and 75 mg/m^2^ CDDP on day 1 of a 21-day cycle (73 patients), or 25 mg/m^2^ vinorelbine on days 1 and 8 with carboplatin (dose equal to an area under the curve of 5; according to the Calvert formula) on day 1 of a 21-day cycle (12 patients). All patients received at least two courses of chemotherapy (range, 2--6 cycles).

Follow-up and statistical analysis
----------------------------------

The dates of recurrence and metastasis and any survival information were obtained from medical records, outpatient follow-up and telephone calls. Outcome data, including disease-free survival (DFS) and overall survival (OS), were calculated from the time of surgery to the date of tumor progression or mortality, respectively, or the last follow-up. The associations between immunohistochemical staining and the patient or tumor characteristics were examined using the χ^2^ test or Fisher's exact test, as appropriate. Survival curves were estimated using the Kaplan-Meier method, while survival differences were compared with the log-rank test. The Cox proportional hazards model was used for multivariate analysis to assess the independent predictive value of β-tubulin expression. All tests were two-sided and P\<0.05 was considered to a indicate statistically significant difference. All statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Frequency of β-tubulin isotype expression in NSCLC
--------------------------------------------------

In the negative control slides, where the antibodies were substituted with PBS, no β-tubulin isotype expression was observed. Positive class III β-tubulin staining was observed in the cytoplasm of 78/85 (91.8%) of the tumor samples, while class II and class IV β-tubulin were positively expressed in 18/85 (21.2%) and 42/85 (49.4%) of the tumor samples, respectively. Representative examples of the β-tubulin immunohistochemical staining are shown in [Figs. 1](#f1-ol-06-01-0220){ref-type="fig"} and [2](#f2-ol-06-01-0220){ref-type="fig"}.

Association of β-tubulin isotype expression and clinico-pathological features in NSCLC
--------------------------------------------------------------------------------------

The 85 patients were grouped according the tumor expression levels of the three β-tubulin isotypes. The patients were divided into high class III (score 3 of ++ or +++) and low class III β-tubulin expression (score 3 of − or +) based on the median class III β-tubulin expression score. As \>50% of the patients did not express class II or class IV β-tubulin (78.8 and 50.6%, respectively), the patients were divided into negative and positive class II/IV β-tubulin groups. The tumor immunohistochemistry results are shown in [Table III](#t3-ol-06-01-0220){ref-type="table"}. Gender, age, histological type, smoking status, lymphatic metastasis status and tumor stage were not significantly associated with β-tubulin class II, III or IV expression ([Table IV](#t4-ol-06-01-0220){ref-type="table"}).

Association of β-tubulin isotype expression with survival in NSCLC
------------------------------------------------------------------

High expression levels of class III β-tubulin were associated with longer median DFS compared with low class III β-tubulin expression (71 vs. 23 months, P=0.033; [Fig. 3A](#f3-ol-06-01-0220){ref-type="fig"}). High expression levels of class III β-tubulin were also associated with a trend towards improved OS (71 vs. 64 months in patients with low level class III β-tubulin expression, P=0.226; [Fig. 3B](#f3-ol-06-01-0220){ref-type="fig"}). DFS and OS were not significantly different in patients with positive or negative expression of class II or class IV β-tubulin ([Figs. 4](#f4-ol-06-01-0220){ref-type="fig"} and [5](#f5-ol-06-01-0220){ref-type="fig"}). Among the other patient characteristics, stage IV disease was associated with a shorter DFS (P=0.020) and shorter OS (P=0.005; data not shown).

Multivariate analysis for DFS and OS
------------------------------------

Multivariate analysis using the Cox proportional hazards model was performed to determine the independent predictive value of the β-tubulin isotypes. The multivariate analysis included the factors of gender, age, histology, stage and the expression of class II, III and IV β-tubulin and indicated that the disease stage and high class III β-tubulin expression were significant independent predictive factors for improved DFS (P=0.004 and P=0.031, respectively). High expression levels of class III β-tubulin yielded a hazard ratio of 0.61, with a 95% confidence interval ranging between 0.294 and 0.944. The tumor stage was correlated independently with OS (P=0.006), while gender, age, histology and class II, III or IV β-tubulin showed no correlation.

Discussion
==========

Since class II, III and IV β-tubulins have been reported to be associated with resistance to tubulin-binding agents ([@b9-ol-06-01-0220]--[@b11-ol-06-01-0220]), the frequency of β-tubulin isotype expression was investigated in R-NSCLC treated with vinorelbine-based adjuvant chemotherapy. The protein expression levels of class II, III and IV β-tubulin were investigated by immunohistochemistry and showed that class III \> class IV \> class II β-tubulin, with respect to relative abundance in R-NSCLC tumors. The expression levels of class II β-tubulin in the advanced tumors in a study by Sève *et al* appeared to be higher than those in R-NSCLC tumors in the present study (57% for ≥26% positive cells vs. 21.2% for ≥10% positive cells). The expression levels of class III β-tubulin appeared to be similiar between the advanced and resected NSCLC samples ([@b14-ol-06-01-0220]). To the best of our knowledge, class IV β-tubulin levels have not been previously reported in NSCLC tumors. No association was identified between the expression levels of the β-tubulin isotypes tested and the clinicopathological characteristics of R-NSCLC.

The present study is the first to show an association between the expression levels of microtubule proteins in R-NSCLC tumor samples and the patient outcome following vinorelbine-based adjuvant chemotherapy. The results of the present study suggested that high tumor expression levels of class III β-tubulin are associated with improved DFS and a trend towards longer OS following vinorelbine-based adjuvant chemotherapy in NSCLC patients. These observations are consistent with a previous study by Sève *et al* ([@b2-ol-06-01-0220]), which demonstrated that the expression levels of class III β-tubulin were correlated with DFS in NSCLC following vinorelbine-based adjuvant chemotherapy. Sève *et al* used semiquantitative immunohistochemistry to analyze the expression of class III β-tubulin in primary NSCLC tumor tissues obtained from 265/482 patients following treatment with vinorelbine/CDDP. It was observed that high levels of β-tubulin III expression were associated with a greater benefit from adjuvant chemo-therapy. These results contrasted with to the correlation between class III β-tubulin expression and chemotherapy in the advanced disease state ([@b14-ol-06-01-0220]). Consequently, this correlation remains controversial. The discrepancy between the predictive value of class III β-tubulin in the metastatic disease and the adjuvant setting is not without precedent. In colorectal cancer, the ability of thymidylate synthase to predict the benefit of chemotherapy differs in operable and advanced disease ([@b15-ol-06-01-0220]--[@b17-ol-06-01-0220]), and at present, the reasons for this difference remain unexplained.

Sève *et al* did not observe a correlation between the expression levels of class II or IV β-tubulin and DFS or OS following vinorelbine-based adjuvant chemotherapy, while in the present study, class II and IV β-tubulins were also not predictive of DFS or OS following vinorelbine-based adjuvant chemotherapy ([@b2-ol-06-01-0220]).

Hirai *et al* ([@b18-ol-06-01-0220]) used an *in vitro* histoculture drug response assay to measure the median effective dose (ED~50~) for vinorelbine. This showed that cells from R-NSCLC tumors expressing high levels of class III β-tubulin exhibited greater chemosensitivity to vinorelbine compared with cells from tumors with low levels of class III β-tubulin expression. This supports the present observation that class III β-tubulin has predictive value in NSCLC patients receiving vinorelbine-based adjuvant chemotherapy.

In conclusion, high levels of class III β-tubulin expression, as assessed by immunohistochemistry, were associated with an increased benefit from adjuvant vinorelbine-based chemo-therapy in patients with operable NSCLC. However, these results are not definitive and further study is required to confirm these observations and determine whether a class III β-tubulin immunohistochemical assay should be developed for use in clinics. Additionally, prospective randomized chemotherapy trials are required to further investigate the predictive value of class III β-tubulin expression, while preclinical investigations are required to clarify the mechanism by which β-tubulin affects the sensitivity of NSCLC cells to chemotherapy.

The authors would like to thank to everyone who contributed to the present study.
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![(A) DFS and (B) OS curves for R-NSCLC patients who received adjuvant chemotherapy, according to class III β-tubulin expression. (A) DFS was inferior in the class III β-tubulin-low patients. DFS, disease-free survival; OS, overall survival; R-NSCLC, resected non-small cell lung cancer.](OL-06-01-0220-g02){#f3-ol-06-01-0220}

![(A) DFS and (B) OS curves for R-NSCLC patients who received adjuvant chemotherapy, according to class II β-tubulin expression. DFS, disease-free survival; OS, overall survival; R-NSCLC, resected non-small cell lung cancer.](OL-06-01-0220-g03){#f4-ol-06-01-0220}

![(A) DFS and (B) OS curves for R-NSCLC patients who recieved adjuvant chemotherapy, according to class IV β-tubulin expression. DFS, disease-free survival; OS, overall survival; R-NSCLC, resected non-small cell lung cancer.](OL-06-01-0220-g04){#f5-ol-06-01-0220}

###### 

Clinicopathological characteristics of the patient population.

  Characteristic              No. of patients   DFS (months)   P-value
  --------------------------- ----------------- -------------- ---------
  Total                       85                               
  Gender                                                       
    Male                      44                31.6           
    Female                    41                30.6           0.87
  Age (years)                                                  
    ≤60                       50                28.9           
    \>60                      38                34.1           0.37
  Histology                                                    
    Adenocarcinoma            48                31.5           
    Squamous cell carcinoma   29                28.7           
    Other                     8                 37.3           0.70
  Smoking                                                      
    Yes                       36                33.2           
    No                        49                29.6           0.53
  Lymphatic metastasis                                         
    Yes                       46                31.4           
    No                        39                30.7           0.91
  Stage                                                        
    IB                        10                47.4           
    IIA                       25                43.2           
    IIB                       33                21.9           
    IIIA                      17                21.6           0.006

DFS, disease-free survival.

###### 

Immunohistochemical scores.

  Score 1   Score 2   Score 3                    
  --------- --------- --------- ---------- ----- ------
  0         \<10      1         Weak       −     ≤1
  1         10--25    2         Moderate   \+    2--3
  2         25--50    3         Strong     ++    4--5
  3         50--75                         +++   ≥6
  4         \>75                                 

###### 

Results of immunostaining for class III, II and IV β-tubulin.

  β-tubulin   Low expression (%)   High expression (%)   Negative expression (%)   Positive expression (%)
  ----------- -------------------- --------------------- ------------------------- -------------------------
  Class III   36 (42.4)            49 (57.6)             \-                        \-
  Class II    \-                   \-                    67 (78.8)                 18 (21.2)
  Class IV    \-                   \-                    43 (50.6)                 42 (49.4)

###### 

Comparison of baseline factors of the 85 patients stratified according to tubulin expression (types II, III and IV β-tubulin).

  Factor                      P-value   β-tubulin III expression (negative)   β-tubulin III expression (positive)   P-value   β-tubulin II expression (negative)   β-tubulin II expression (positive)   P-value   β-tubulin IV expression (negative)   β-tubulin IV expression (positive)                                   
  --------------------------- --------- ------------------------------------- ------------------------------------- --------- ------------------------------------ ------------------------------------ --------- ------------------------------------ ------------------------------------ ------ ------- ---- ------ ---- ------
  Gender                      0.473                                                                                                                                0.717                                                                                                                           0.748                    
    Male                                17                                    38.6                                  27        61.4                                                                      34        77.3                                 10                                   22.7           23   52.3   21   47.7
    Female                              19                                    46.3                                  22        53.7                                                                      33        80.5                                 8                                    19.5           20   48.8   21   51.2
  Age (years)                 0.600                                                                                                                                0.446                                                                                                                           0.897                    
    ≤60                                 20                                    40.0                                  30        60.0                                                                      38        76.0                                 12                                   24.0           25   50.0   25   50.0
    \>60                                16                                    45.7                                  19        54.3                                                                      29        82.9                                 6                                    17.1           18   51.4   17   48.6
  Histology                   0.724                                                                                                                                0.962                                                                                                                           0.308                    
    Adenocarcinoma                      19                                    39.6                                  29        60.4                                                                      38        79.2                                 10                                   20.8           22   45.8   26   54.2
    Squamous cell carcinoma             14                                    48.3                                  15        51.7                                                                      23        19.3                                 6                                    20.7           15   51.7   14   48.3
    Other                               3                                     37.5                                  5         62.5                                                                      6         75.0                                 2                                    25.0           6    75.0   2    25.0
  Smoking                     0.318                                                                                                                                0.840                                                                                                                           0.729                    
    No                                  23                                    46.9                                  26        53.1                                                                      39        79.6                                 10                                   20.4           24   49.0   25   51.0
    Yes                                 13                                    36.1                                  23        63.9                                                                      28        77.8                                 8                                    22.2           19   52.8   17   47.2
  Lymphatic metastasis        0.514                                                                                                                                0.890                                                                                                                           0.323                    
    Yes                                 18                                    39.1                                  28        60.9                                                                      36        78.3                                 10                                   21.7           21   46.7   24   53.3
    No                                  18                                    46.2                                  21        53.8                                                                      31        79.5                                 8                                    21.2           21   55.3   17   44.7
  Stage                       0.603                                                                                                                                0.652                                                                                                                           0.336                    
    IB                                  5                                     50.0                                  5         50.0                                                                      9         90.0                                 1                                    10.0           4    40.0   6    60.0
    IIA                                 8                                     32.0                                  17        68.0                                                                      20        80.0                                 5                                    20.0           13   52.0   12   48.0
    IIB                                 16                                    48.5                                  17        51.5                                                                      24        72.7                                 9                                    27.3           20   60.6   13   39.4
    IIIA                                7                                     41.2                                  10        58.8                                                                      14        82.4                                 3                                    17.6           6    35.3   11   64.7
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